Testicular cancer commonly affects men aged between 20 and 35 years. It accounts up to 2% of cancers diagnosed in men, although the lifetime risk of mortality is less than 1%. Screening for testicular cancer is commonly performed by physician, who performs a physical examination, or self-examination by the patient. However, there is little evidence that documents the accuracy of such examinations. This review identified that no randomised controlled trials have been performed to evaluate the effectiveness of screening for testicular cancer. In the absence of high quality evidence, male patients with an increased risk of developing testicular cancer should be informed of the potential benefits and harms associated with screening.
Screening for testicular cancer
Have your say!
'Your views on The Cochrane Library: survey'
Published Online:
April 13, 2011
Health topics:
More like this
- Surgery for upper tract transitional cell carcinoma
- Major bladder surgery improves chances of survival for people with bladder cancer that has invaded the muscle, but more studies are needed
- Local treatment with Bacillus Calmette-Guérin following surgery for superficial bladder cancer reduces the risk of the cancer returning.
- Men and women with Ta and T1 bladder cancer were given two prophylactic treatments of BCG and Mitomycin C and compared.
- Five-alpha-reductase inhibitor drugs, such as finasteride or dutasteride, reduce the risk prostate cancer in men who have routine prostate cancer screening
